In this issue:
Labetuzumab govitecan in refractory mCRC
Good prognosis for non-V600BRAF CRC
Second- or third-line cetuximab in mCRC
Early SIRT no benefit in mCRC
TAS-102 + bevacizumab for refractory mCRC
Nivolumab for MMR deficient/high MSI mCRC
Capecitabine + bevacizumab maintenance treatment
Genetic analysis faster with ctDNA
Salvage surgery for recurrent rectal cancer
Multimodal treatment of locally advanced rectal cancer
Please login below to download this issue (PDF)